非酒精性脂肪性肝病相关慢性肾病研究进展

doi:10.3969/j.issn.1672-5069.2016.03.033

Abstract

Abstract: Non-alcoholic fatty liver diseases （NAFLD） is an acquired metabolic stress-induced liver diseases associated with insulin resistance and genetic susceptibility，which has become one of the global public health problems. Accumulating evidence suggests that NAFLD may be associated with an increased prevalence and incidence of chronic kidney disease （CKD）. In this review，the evidence of NAFLD related to CKD，and the putative mechanisms by which nonalcoholic fatty liver disease contributes to kidney damage will be reviewed，and we hope it will provide guidance and recommendations for more comprehensive management of patients with nonalcoholic fatty liver disease or chronic kidney disease.

Key words: Nonalcoholic fatty liver disease, Chronic kidney disease, Metabolic syndrome, Insulin resistance

Lei Ting,Li Liangping. Chronic kidney disease in patients with nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 373-376.

References

[1] Review T，LaBrecque DR，Abbas Z，et al. World gastroenterology organisation global guidelines:Nonalcoholic fatty liver disease and nonalcoholicsteatohepatitis. J Clin Gastroenterol，2014，48（6）:467-473.
[2] James MT，Hemmelgarn BR，Tonelli M. Early recognition and prevention of chronic kidney disease.Lancet，2010，375（9722）:1296-1309.
[3] Younossi ZM，Stepanova M，Afendy M，et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.Clin Gastroenterol Hepatol，2011，9（6）:524-530.
[4] Welsh JA，Karpen S，Vos MB.Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents，1988-1994 to 2007-2010. J Pediatr，2013，162（3）:496-500.
[5] Okanoue T，Umemura A，Yasui K，et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan.J Gastroenterol Hepatol，2011，26（1）:153-162.
[6] 梁国威，徐旭，刘耘，等. 北京地区成年人血尿酸和非酒精性脂肪肝相关性研究. 医学研究杂志，2011，40（12）：66-69.
[7] 秦恳，周婷，吴琴琴，等. 成都地区非酒精性脂肪肝与代谢综合征相关性研究. 现代预防医学，2012，39（10）：2395-2397.
[8] 李萍，傅晓英，许谷根. 广州地区健康体检人群非酒精性脂肪肝与代谢综合征的发病情况分析. 当代医学，2012，18（5）：162-163.
[9] 陆喜燕，董国庆，钟丽华，等. 单纯性肥胖患儿非酒精性脂肪性肝病与胰岛素抵抗. 实用儿科临床杂志，2012，27（11）：859-861.
[10] Stauffer ME，Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One，2014，9（1）:e84943.
[11] Mallett A，Patel C，Salisbury A，et al. The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet J Rare Dis，2014，9:98.
[12] Zhang L，Wang F，Wang L，et al. Prevalence of chronic kidney disease in China:a cross-sectional survey. Lancet，2012，379（9818）:815-822.
[13] Coresh J，Astor BC，Greene T，et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third National Health and Nutrition Examination Survey. Am J Kidney Dis，2003，41（1）:1-12.
[14] Johns BR，Pao AC，Kim SH. Metabolic syndrome，insulin resistance and kidney function in non-diabetic individuals. Nephrol Dial Transplant，2012，27（4）:1410-1415.
[15] Ferraro PM，Lupo A，Yabarek T，et al. Metabolic syndrome，cardiovascular disease，and risk for chronic kidney disease in an Italian cohort:analysis of the INCIPE study. Metab Syndr Relat Disord，2011，9（5）:381-388.
[16] Thomas G，Sehgal AR， Kashyap SR，et al. Metabolic syndrome and kidney disease:a systematic review and meta-analysis. Clin J Am Soc Nephrol，2011，6（10）:2364-2373.
[17] Schuppan D，Schattenberg JM. Non-alcoholic steatohepatitis:pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol，2013（Suppl 1）:68-76.
[18] Pham H，Robinson-Cohen C，Biggs ML，et al. Chronic kidney disease，insulin resistance，and incident diabetes in older adults.Clin J Am Soc Nephrol，2012，7（4）:588-594.
[19] Targher G，Chonchol M，Zoppini G，et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease:is there a link J Hepatol，2011，54（5）:1020-1029.
[20] Guleria A，Duseja A，Kalra N，et al. Patients with non-alcoholic fatty liver disease（NAFLD） have an increased risk of atherosclerosis and cardiovascular disease. Trop Gastroenterol，2013，34（2）:74-82.
[21] Targher G，Bertolini L，Chonchol M，et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.Diabetologia.2010，53（7）:1341-1348.
[22] Hwang ST，Cho YK，Yun JW，et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J，2010，40（6）:437-442.
[23] Targher G，Pichiri I，Zoppini G，et al. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med，2012，29（2）:220-226.
[24] Targher G，Bertolini L，Rodella S，et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol，2010，5（12）:2166-2171.
[25] Yilmaz Y，Alahdab YO，Yonal O，et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease:association with liver fibrosis. Metabolism，2010，59（9）:1327-1330.
[26] Yasui K，Sumida Y，Mori Y，et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease.Metabolism，2011，60（5）:735-739.
[27] Machado MV， Goncalves S，Carepa F，et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int，2012，32（2）:241-248.
[28] Byrne CD.Dorothy Hodgkin Lecture 2012:non-alcoholic fatty liver disease，insulin resistance and ectopic fat:a new problem in diabetes management.Diabet Med，2012，29（9）:1098-1107.
[29] Sabio G，Davis RJ. cJun NH2-terminal kinase 1（JNK1）:roles in metabolic regulation of insulin resistance. Trends Biochem Sci，2010，35（9）:490-496.
[30] Sharma M，Mitnala S，Vishnubhotla RK，et al. The riddle of nonalcoholic fatty liver disease:Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol，2015，5（2）:147-158.
[31] Tilg H，Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology，2010，52（5）:1836-1846.
[32] Vaziri ND，Liu SM，Lau WL，et al. High amylase resistant starch diet ameliorates oxidative stress，inflammation，and progression of chronic kidney disease. PLoS One，2014，9（12）:e114881.
[33] Ix JH，Sharma K.Mechanisms linking obesity，chronic kidney disease，and fatty liver disease:the roles of fetuin-A，adiponectin，and AMPK. J Am Soc Nephrol，2010，21（3）:406-412.
[34] Kadowaki T，Yamauchi T，Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS.FEBS Lett，2008，582（1）:74-80.
[35] Sharma K，Ramachandrarao S，Qiu G，et al. Adiponectin regulates albuminuria and podocyte function in mice.J Clin Invest，2008，118（5）:1645-1656.
[36] Declèves AE，Mathew AV，Cunard R，et al. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol，2011，22（10）:1846-1855.
[37] Gurkan C，Halil G，Hasan G，et al. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease.Saudi J Gastroenterol，2015，21（3）:139-145.

Chronic kidney disease in patients with nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[3]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[6]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[7]	Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.
[8]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[9]	Xu Jian, Lu Xiangyu, Gong Jun, et al.. Prevalence of metabolic syndrome and new-onset cholelithiasis in the elderly [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 133-136.
[10]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[11]	Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.
[12]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[13]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[14]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[15]	Ge Jianxiang, Sun Yezi, Zhao Yun.. Application of entecavir in the treatment of patients with HBV-related cirrhosis complicated by hepatogenous diabetes and its influence on indexes of glucose metabolism [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 677-680.